50 HIV patients were followed for 12 months, out of which 31 patients • for 24 months.
Cheek thickness measured with ultrasonography showed significant im • provement in cheek thickness.
Mean visual analogue scale improved significantly.
• The Assessment of Body Change and Distress showed significant in • crease in satisfaction with personal body image and indicated a less negative impact on patients' relational life after the procedure.
The Beck Depression Scale showed a significant improvement in the pas • sage from moderate to mild depression. An overall improvement in the self-esteem of the patients was achieved.
• Aquamid • ® provided stable correction over time with no complications.
Aquamid is a safe soft-tissue filler and is an appropriate treatment option • in restoring facial contours in HIV-infected patients.
S U M M A R Y B A C K G R O U N D a n d I N T R O D U C T I O N
Facial lipoatrophy is defined as the reduction in buccal and orbital fat pads with a • more global loss of fat within the subcutaneous tissue.
It is the most common and distressing sign of human immunodeficiency virus-related lipoatrophy.
• At present, aesthetic procedures are the best solution to alleviating the effects of this stigma • tizing syndrome.
Injectable polyacrylamide hydrogel (Aquamid • ® ) is non-absorbable, homogeneous and particle-free consisting of 97,5% water and 2,5% cross-linked polyacrylamide.
Favorable results with maximum aesthetic outcome with the use of • polyacrylamide hydrogel for reconstruction of facial lipoatrophy on the face are being reported.
The authors:
• -evaluated efficacy and demonstrated improvement in QoL (Quality of Life) in HIV patients.
-determined long-term tolerance, durability and safety of Aquamid in HIV patients.
Patients and Methods

Study objective
Clinical results and Discussion 50 consecutive HIV type 1 patients attending the Modena University Hospital HIV Metabolic Clinic in Italy were invited to participate in the study. The diagnosis of facial lipoatrophy was clinically defined as a moderate to severe thinning of the Bichat fat pad of the subcutaneous layer of the cheeks and zygomatic area and a deepening of the naso labial folds. Patients were asked to present pre-facial lipoatrophy photographs which were compared to the their current facial appearance. Facial lipoatrophy was confirmed by ultrasonography.
Among the inclusion criteria were CD4 cell count greater than 100 cells/µl and patients with previous permanent fillers at the same site were excluded. All 50 patients completed the 12 months follow-up period. Thirty-one of them reached the 24 months follow-up.
The purpose of the study is to evaluate the efficacy of polyacrylamide hydrogel (Aquamid) injections over a 12 month period and to demonstrate an improvement in the quality of life of human immunodeficiency virus-infected patients. Furthermore to determine the long-term tolerance, durability and safety of the polyacrylamide injections.
Clinically no significant side effects were detected at the 12 months follow-up. Four percent of the patients experienced a transitory swelling or redness lasting from 12-24 hours after the procedure. No infection, color alteration or granuloma formation was registered. The average number of procedures was 6.1 or each patient.
The following variables were assessed.
Cheek thickness measured with standard ultrasonography showed a significant improvement in • contour.
Visual analogue scale also showed a significant improvement already at the 6 months follow-up. Polyacrylamide hydrogel (Aquamid) has been shown to provide stable correction over time when used in appropriate volumes. No local complications, aggravated tissue reaction, or interference with facial movement or function was noted in a significantly immunocompromised population over an extended duration.
Photographic and psychological assessment test evidence of the cosmetic results are consistent with a lasting improvement in the self-esteem of the patients.
Polyacrylamide hydrogel (Aquamid) has been shown to be an appropriate treatment option in restoring facial contours in the immunocompromised, human immunodeficiency virus-infected patient subset and is recommended as a safe soft-tissue filler material in aesthetic practice.
relational life after the procedure with the Polyacrylamide hydrogel injections.
The Bech depression Inventory Scale showed significant improvement which is consistent with a • passage from moderate to mild depression.
Free fat transfer is another option and represents a well-established technique but is not ideal for HIV patients with lipoatrophy. Other fillers such as polylactic acid have been in use but are limited in time because of resorption. . Before and after images of a 42-year old man with moderate lipoatrophy of the face. Seven procedures of max 2 ml Aquamid per session were required to achieve the result.
